syapse has a research partnership with the fda's Center of Excellence in Oncology

, syapse, which specializes in precision medicine, signed a multi-year research collaboration agreement with the fda's Center of Excellence in Oncology (oce), focusing on the use of real-world evidence (rwe) to support regulatory decision-making. syapse and oce will work with the relevant departments of the fda to address key regulatory issues related to testing and treatment models, dosages, safety, and oncology efficacy, with a focus on precision medicine.Syapse, a biotech company, helps doctors choose the precision medicine that best suits their patients by integrating previously fragmented data on clinical, molecular, therapeutic and therapeutic outcomes. syapse's data-sharing network brings together rwe from multiple hospital systems, including molecular sequencing data such as anonymous electronic medical records, pathology reports, and dna. syapse has established the world's largest health learning network of data provider-driven precision medicine data. The company's partners include advocate aurora health care, commonspirit health, henry ford health system, providence st. Joseph Health and Seoul National University Hospital. Syapse's goal is to strive for the best individualized care for cancer patients anywhere and on any income.as part of this collaboration, syapse and fda will look at ways to obtain rwe from a variety of sources, beyond electronic health records .ehrs. The framework for fda's real-world evidence program describes the challenges of obtaining comprehensive data from ehr and insurance claims records, as well as the difficulty of tracing the source of the data. The collaboration will use actual data from many source systems, including clinical data from ehr and registries, as well as molecular data from test laboratories, and, on that basis, seek to locally test the applicability of such multi-source rwe for its regulatory applicability.In addition, syapse and fda will examine solid and malignant blood tumors at real-world endpoints to describe the use and clinical application of molecular testing, to understand differences in efficacy and adverse events between patients receiving precision medicine therapy and clinical trial populations, and to include patient efficacy reports in rwe.
(
medicine Mingkangde)